Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
47.98M | 96.73M | 48.58M | 18.26M | 9.33M | Gross Profit |
47.98M | 96.37M | 47.03M | 17.14M | -57.67M | EBIT |
-73.36M | 21.48M | -42.20M | -87.97M | -79.11M | EBITDA |
-73.36M | 25.77M | -42.26M | -87.17M | -76.93M | Net Income Common Stockholders |
-68.57M | 22.81M | -48.03M | -91.30M | -77.52M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
52.89M | 76.33M | 109.11M | 146.40M | 126.91M | Total Assets |
110.54M | 182.39M | 124.80M | 171.07M | 153.45M | Total Debt |
4.30M | 5.54M | 6.65M | 7.33M | 7.84M | Net Debt |
-48.59M | -70.79M | -102.46M | -105.25M | -77.37M | Total Liabilities |
64.42M | 75.50M | 48.87M | 82.78M | 21.41M | Stockholders Equity |
46.12M | 106.89M | 75.93M | 88.29M | 132.04M |
Cash Flow | Free Cash Flow | |||
-23.44M | -32.99M | -7.73M | -64.31M | -86.03M | Operating Cash Flow |
-23.44M | -32.99M | -7.73M | -64.35M | -85.87M | Investing Cash Flow |
0.00 | 0.00 | 33.81M | 7.67M | 10.47M | Financing Cash Flow |
0.00 | 221.00K | -29.55M | 84.05M | 130.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.35B | 3.41 | -40.83% | 2.89% | 18.11% | 2.60% | |
48 Neutral | $39.69M | 10.83 | -89.62% | ― | -71.68% | -397.61% | |
48 Neutral | $37.91M | ― | -33.25% | ― | -97.33% | -136.16% | |
46 Neutral | $35.51M | ― | -139.16% | ― | 20.58% | 15.90% | |
35 Underperform | $43.57M | ― | 607.06% | ― | ― | 55.67% | |
34 Underperform | $37.32M | ― | -49.69% | ― | ― | 38.98% | |
31 Underperform | $23.04M | ― | -388.29% | ― | ― | 38.50% |
On April 28, 2025, Spero Therapeutics announced the appointment of Esther Rajavelu as President and Chief Executive Officer, effective May 2, 2025. Rajavelu, who has been serving as Interim President and CEO since January 2025, will also continue her roles as Chief Financial Officer and Treasurer. This leadership transition follows the mutual separation of former CEO Sath Shukla, who will step down on the same effective date. The company is focused on advancing its PIVOT-PO Phase 3 trial for tebipenem HBr, with Rajavelu’s leadership expected to strengthen Spero’s strategic initiatives and partnerships, particularly with GSK.
Spark’s Take on SPRO Stock
According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.
Spero Therapeutics is currently facing financial and operational challenges, highlighted by declining revenues and increased losses. The financial performance and technical analysis suggest a cautious outlook, while the earnings call provides some optimism through strategic partnerships and potential milestone payments. However, the negative valuation metrics and recent clinical trial setbacks weigh heavily on the stock score, resulting in an overall score of 53.
To see Spark’s full report on SPRO stock, click here.